Take advantage of the latest tools, techniques, and deep healthcare expertise to create scalable resources, precision insights, and actionable ideas.
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSObesity is a chronic complex disease defined by excessive fat deposits that can impair health. Obesity heightens the risk of type 2 diabetes (T2DM), heart disease and certain cancers. It can impact bone health, reproduction, morbidity, disability, and quality of life. The 2019 Global Burden of Disease study estimates that obesity contributed to approximately 5 million deaths globally. Over the years, several anti-obesity medications (AOM) have reached the market but failed after widespread use due to serious adverse effects, including cardiovascular events, suicidality, abuse, dependence, and cancer. Advancements have been made in elucidating the role of entero-pancreatic hormones in the regulation of feeding, appetite and glycemia that has led to the development of glucagon like peptide-1 receptor (GLP1R) agonists as safe and effective treatments for T2DM and obesity.
The first GLP1R agonist to reach the market since 2014 for obesity was Novo Nordisk's semaglutide (WEGOVY), which was approved by the US FDA in June 2021. Semaglutide quickly emerged as a blockbuster, reaching sales of USD 7.73 billion in 2023. Later two other drugs were approved for the treatment of obesity — Lilly's tirzepatide (ZEPBOUND), a glucose-dependent insulinotropic polypeptide receptor GIPR)/GLP1R co-agonist, and Rhythm Pharmaceuticals' setmelanotide (IMCIVREE), a melanocortin 4 receptor (MC4R) agonistic peptide.
This article provides an update on current treatment options for obesity and outlines the latest development activities, including ongoing clinical trials of key experimental drugs with data sourced from IQVIA Pipeline Link and IQVIA Trial Link.
Download the full article to learn more about the treatment options for obesity, obesity pipeline insights, the clinical trial landscape, and novel therapies in early development.
Take advantage of the latest tools, techniques, and deep healthcare expertise to create scalable resources, precision insights, and actionable ideas.
Be proactive about growing your brand using the latest in data, analytics, and domain expertise.
Strengthen your portfolio by making more informed decisions and prepare for the impact of new research discoveries.
Get an up to date view of key performance indicators globally, regionally, or locally.
IQVIA Analytics Link Ecosystem establishes deep connections across our key data assets.